Santen Pharmaceutical Co., Ltd.

4536 · TSE

Public Market Listing

4536TSE

TSE primary exchange listing

Live quotes, historical charts, and market capitalization for Santen Pharmaceutical Co., Ltd. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
VEGF-A / FGF-2 (dual blockade)Protein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
December 2028 (1)
RC28-EPhase 3Diabetic Macular Edema (DME), wAMD
Est. primary completion 2028-12-01 · NCT07936487 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

July 2026WithdrawalRC28-ERemeGen voluntarily withdraws the RC28-E DME application in China on NMPA review advice
China, NMPA · RemeGen Co., Ltd. · Source ↗
30 September 2025Topline resultRC28-EDME Phase 3 vs aflibercept (NCT05885503) met its primary endpoint
China · RemeGen Co., Ltd. and Santen Pharmaceutical Co., Ltd. · Source ↗
30 September 2025Filing acceptedRC28-EChina's CDE accepts the RC28-E BLA for diabetic macular edema
China, NMPA · RemeGen Co., Ltd. and Santen Pharmaceutical Co., Ltd. · Source ↗

Financial reports

No financial reports recorded.